Literature DB >> 7246580

Hypocalcemia with osteoblastic metastases in patient with prostate carcinoma. A cause of secondary hyperparathyroidism.

R C Smallridge, H L Wray, M Schaaf.   

Abstract

A 68 year old man with prostatic carcinoma and extensive painful osteoblastic metastases was discovered to have hypocalcemia (serum calcium 7.1 mg/dl) without evidence of hypoalbuminemia, renal failure or malabsorption. Baseline studies revealed hypocalciuria (24 hour urine calcium less than 5 mg/day), normal serum phosphate (3.4 mg/dl), low tubular reabsorption of phosphate (68 percent), undetectable serum calcitonin, normal serum 25-hydroxyvitamin D, slightly elevated serum parathyroid hormone level and increased urinary cyclic AMP (8.87 mumol/g creatinine). These studies were compatible with secondary hyperparathyroidism. The intravenous administration of parathyroid extract produced no further change in urinary phosphate but a 25-fold increase in nephrogenous cyclic AMP. Three days administration of intramuscular parathyroid extract slowly and temporarily restored serum calcium to normal levels while increasing urinary cyclic AMP and phosphate. Chemotherapy with cyclophosphamide and 5-fluorouracil rendered the patient free of pain while reducing serum acid and alkaline phosphatase levels and restoring serum total and ionized calcium and urinary cyclic AMP excretion to normal.

Entities:  

Mesh:

Year:  1981        PMID: 7246580     DOI: 10.1016/0002-9343(81)90292-8

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  10 in total

1.  Refractory hypocalcaemia complicating metastatic prostatic carcinoma.

Authors:  Christopher Rizzo; Sandro Vella; Mario J Cachia
Journal:  BMJ Case Rep       Date:  2015-06-29

2.  Hungry bone syndrome secondary to prostate cancer successfully treated with radium therapy.

Authors:  Vishnu Vardhan Garla; Sohail Salim; Karthik Reddy Kovvuru; Angela Subauste
Journal:  BMJ Case Rep       Date:  2018-07-06

3.  Hypocalcemia due to avid calcium uptake by osteoblastic metastases of prostate cancer.

Authors:  M Szentirmai; C Constantinou; J M Rainey; J E Loewenstein
Journal:  West J Med       Date:  1995-12

Review 4.  A review of drug-induced hypocalcemia.

Authors:  George Liamis; Haralampos J Milionis; Moses Elisaf
Journal:  J Bone Miner Metab       Date:  2009       Impact factor: 2.626

5.  89Sr therapy: strontium plasma clearance in disseminated prostatic carcinoma.

Authors:  G M Blake; J F Wood; P J Wood; M A Zivanovic; V J Lewington
Journal:  Eur J Nucl Med       Date:  1989

6.  Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate.

Authors:  G M Blake; M A Zivanovic; A J McEwan; D M Ackery
Journal:  Eur J Nucl Med       Date:  1986

Review 7.  Severe and refractory hypocalcaemia secondary to osteoblastic bone metastases in bladder signet ring carcinoma: A case report and literature review.

Authors:  Wanling Zeng; Du Soon Swee
Journal:  Medicine (Baltimore)       Date:  2022-07-01       Impact factor: 1.817

8.  Hypocalcemia in patients with prostate cancer.

Authors:  S C Kukreja; A Shanmugam; T E Lad
Journal:  Calcif Tissue Int       Date:  1988-12       Impact factor: 4.333

9.  Paraneoplastic hypocalcemia-induced heart failure in advanced breast cancer: A case report and literature review.

Authors:  Alberto Farolfi; Cristiano Ferrario; Michele Aquilina; Lorenzo Cecconetto; Andreas Tartaglia; Toni Ibrahim; Luigi Serra; Devil Oboldi; Maurizio Nizzoli; Andrea Rocca
Journal:  Oncol Lett       Date:  2015-06-05       Impact factor: 2.967

10.  Severe Hypocalcemia in a Patient with Recurrent Chondrosarcoma.

Authors:  Jung Nam Eun; Yoo Duk Choi; Jeong Ho Lee; Yun Ah Jeong; Jee Hee Yoon; Hee Kyung Kim; Ho-Cheol Kang
Journal:  Intern Med       Date:  2017-07-15       Impact factor: 1.271

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.